ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2015
Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 51 citations in OpenAlex.
- MicroRNA-379 Modulates Prostate-Specific Antigen Expression Through Targeting the Androgen Receptor in Prostate Cancer.Cancers · 2025Article
- Article
- Review
- Breast Cancer and Bone Mineral Density in a U.S. Cohort of Middle-Aged Women: Associations with Phosphate Toxicity.Cancers · 2023Article
- Macromorphometric Analysis of Metastatic Lesions in Bones due to Breast Cancer: Contribution to Human Identification.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Review
- Secreted microRNAs in bone metastasis.Journal of bone and mineral metabolism · 2023Review
- Bone Metastases and Health in Prostate Cancer: From Pathophysiology to Clinical Implications.Cancers · 2023Review
- Differentiation of predominantly osteolytic from osteoblastic spinal metastases based on standard magnetic resonance imaging sequences: a comparison of radiomics model versus semantic features logistic regression model findings.Quantitative imaging in medicine and surgery · 2022Article
- Quantitative Analysis of SPECT-CT Data in Metastatic Breast Cancer Patients-The Clinical Significance.Cancers · 2022Article
- DOTA Conjugate of Bisphosphonate and PSMA-Inhibitor: A Promising Combination for Therapy of Prostate Cancer Related Bone Metastases.Frontiers in nuclear medicine · 2022Article
- Safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors.Frontiers in oncology · 2022Article
- Exosomes derived from PC-3 cells suppress osteoclast differentiation by downregulating miR-148a and blocking the PI3K/AKT/mTOR pathway.Experimental and therapeutic medicine · 2021Article
- Article
- Role of betulinic acid derivative SH-479 in triple negative breast cancer and bone microenvironment.Oncology letters · 2021Article
- Osteoimmuno-Oncology: Therapeutic Opportunities for Targeting Immune Cells in Bone Metastasis.Cells · 2021Review
- Clinical Features and Serological Markers Risk Model Predicts Overall Survival in Patients Undergoing Breast Cancer and Bone Metastasis Surgeries.Frontiers in oncology · 2021Article
- Breast Cancer and Microcalcifications: An Osteoimmunological Disorder?International journal of molecular sciences · 2020Review
- Role of the bone microenvironment in bone metastasis of malignant tumors - therapeutic implications.Cellular oncology (Dordrecht, Netherlands) · 2020Review
- The Role of Adipokines and Bone Marrow Adipocytes in Breast Cancer Bone Metastasis.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several cancers tend to metastasize to bone, leading to osteolytic or osteoblastic bone lesions. The respective phenotypes of bone destruction and bone formation vary in clinical features, including incidence, prognosis, skeletal-related events and bone biomarkers. In addition, different molecular mechanisms explain the difference in phenotype. For example, molecules involved in osteolytic bone metastases (represented with breast cancer) include parathyroid hormone-related protein, transforming growth factor-β, while in osteoblastic lesions (represented with prostate cancer), endothelin-1 and morphogenetic proteins, etc. play a more important role in bone formation. It is important for us to understand the differences of bone metastases between two phenotypes to help clinicians to understand the underlying mechanisms, behaviors and therapies in development and currently available for bone metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.